These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 39218743)

  • 1. Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis.
    Wenzel M; Cano Garcia C; Humke C; Hoeh B; Steuber T; Tilki D; Merseburger AS; Kluth LA; Chun FKH; Mandel P
    Eur Urol Oncol; 2024 Aug; ():. PubMed ID: 39218743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
    Merseburger AS; Agarwal N; Bjartell A; Uemura H; Soto AJ; Bhaumik A; Böhm J; Tran N; Krochmann N; Nematian-Samani M; Mundle SD; Brookman-May SD; Lopez-Gitlitz A; McCarthy SA; Chi K; Chowdhury S
    BJU Int; 2024 Dec; 134(6):982-991. PubMed ID: 38940282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of PSA nadir, PSA response and time to PSA nadir on overall survival in real-world setting of metastatic hormone-sensitive prostate cancer patients.
    Wenzel M; Hoeh B; Hurst F; Koll F; Cano Garcia C; Humke C; Steuber T; Tilki D; Traumann M; Banek S; Chun FKH; Mandel P
    Prostate; 2024 Sep; 84(13):1189-1197. PubMed ID: 38812332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
    Yanagisawa T; Fukuokaya W; Hatakeyama S; Narita S; Muramoto K; Katsumi K; Takahashi H; Urabe F; Mori K; Tashiro K; Iwatani K; Shimomura T; Habuchi T; Kimura T
    Prostate; 2025 Feb; 85(2):165-174. PubMed ID: 39417629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
    Small EJ; Chi KN; Chowdhury S; Bevans KB; Bhaumik A; Saad F; Chung BH; Karsh LI; Oudard S; De Porre P; Brookman-May SD; McCarthy SA; Mundle SD; Uemura H; Smith MR; Agarwal N
    Eur Urol Oncol; 2024 Aug; 7(4):844-852. PubMed ID: 38072759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
    Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Juárez Soto Á; Uemura H; Ye D; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
    Ann Oncol; 2023 May; 34(5):477-485. PubMed ID: 36858151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
    Saad F; Small EJ; Feng FY; Graff JN; Olmos D; Hadaschik BA; Oudard S; Londhe A; Bhaumik A; Lopez-Gitlitz A; Thomas S; Mundle SD; Chowdhury S; Smith MR
    Eur Urol; 2022 Feb; 81(2):184-192. PubMed ID: 34916086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prostate-specific antigen response in patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or abiraterone acetate: A retrospective cohort study.
    Lowentritt B; Pilon D; Waters D; Rossi C; Muser E; Kurteva S; Shah A; Khilfeh I; Du S; Ellis L; Lefebvre P; Brown G
    Urol Oncol; 2023 May; 41(5):252.e19-252.e27. PubMed ID: 37080833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.
    López-Abad A; Ramírez Backhaus M; Server Gómez G; Cao Avellaneda E; Moreno Alarcón C; López Cubillana P; Yago Giménez P; de Pablos Rodríguez P; Juan Fita MJ; Climent Durán MÁ; Guardiola Ruiz I; Vidal Crespo N; Artés Artés M; Montoya Chinchilla R; Moreno Avilés J; Guzmán Martínez-Valls PL; López González PÁ
    Prostate Int; 2024 Mar; 12(1):20-26. PubMed ID: 38523897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apalutamide for prostate cancer: Multicentre and multidisciplinary real-world study of 227 patients.
    Sánchez JC; Picola N; Rodriguez-Vida A; Costa M; Castañeda DM; Márquez MP; Rodriguez JM; Gaya JM; Bravo A; Buisan O; Servian P; Suarez JF; Felip MM; Caparrós MJR; Asensio AA; Vilaseca A
    Cancer Med; 2023 Dec; 12(24):21969-21977. PubMed ID: 38063364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone.
    Sheng IY; Fallah J; Gupta R; Li H; Allman K; Martin A; Barata P; Ornstein MC; Gilligan TD; Rini BI; Garcia JA
    Target Oncol; 2020 Aug; 15(4):477-483. PubMed ID: 32661959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.
    Myint ZW; Kolesar JM; McCorkle JR; Wu J; Ellis CS; Otto DE; Wang P
    Med Sci Monit; 2022 Oct; 28():e938091. PubMed ID: 36229939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
    Rescigno P; Lorente D; Bianchini D; Ferraldeschi R; Kolinsky MP; Sideris S; Zafeiriou Z; Sumanasuriya S; Smith AD; Mehra N; Jayaram A; Perez-Lopez R; Mateo J; Parker C; Dearnaley DP; Tunariu N; Reid A; Attard G; de Bono JS
    Eur Urol; 2016 Nov; 70(5):724-731. PubMed ID: 26965561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
    Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Soto ÁJ; Uemura H; Ye DW; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
    Future Oncol; 2024 Mar; 20(10):563-578. PubMed ID: 38126311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.
    Tseng CS; Yang JH; Huang SW; Wang YJ; Chen CH; Pu YS; Cheng JC; Huang CY
    BMC Cancer; 2023 Jun; 23(1):568. PubMed ID: 37340337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
    Smith MR; Antonarakis ES; Ryan CJ; Berry WR; Shore ND; Liu G; Alumkal JJ; Higano CS; Chow Maneval E; Bandekar R; de Boer CJ; Yu MK; Rathkopf DE
    Eur Urol; 2016 Dec; 70(6):963-970. PubMed ID: 27160947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.